Company / Return on Equity (ROE)
Harmony Biosciences Holdings, Inc. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
18.2%
FY2025
5-year range
18.2% / 45.1%
FY2022-FY2025
Trend
-17.4%
vs FY2024
Sector context
#24 of 190
Health Care
What the data says
Harmony Biosciences Holdings, Inc.'s return on equity (roe) of 18.2% is higher than 87% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has declined for 3 consecutive years, from 45.1% in FY2022 to 18.2% in FY2025.
Based on SEC 10-K filings.
18.2% in FY2025 with a 3-year CAGR of -26.8%. Top quartile in the Health Care sector.
Declined from 27.6% to 18.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -26.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
+136.2% above sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 17.4% year-over-year.
- Currently 68.7pp above the Health Care sector average.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 18.2% | -17.4% |
| FY2024 | 22.1% | -20.0% |
| FY2023 | 27.6% | -38.8% |
| FY2022 | 45.1% | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026